.jpg)
AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer
AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer
AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.
Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation
Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation
Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies
Tetraphase Reports First Quarter 2013 Financial Results
Tetraphase Reports First Quarter 2013 Financial Results
WATERTOWN, Mass.--(BUSINESS WIRE)--
Tetraphase Pharmaceuticals, Inc. (TTPH) today reported financial results for the first quarter ended March 31, 2013.
Frost & Sullivan Recognizes Selventa's Proprietary Systems Diagnostics Technology Platform
Frost & Sullivan Recognizes Selventa's Proprietary Systems Diagnostics Technology Platform
SysDx helps doctors make the best therapeutic decisions by providing an in-depth understanding of intervening biochemical mechanisms
Affinnova Wins SBANE Innovation Award
Affinnova Wins SBANE Innovation Award
Waltham-Based Software and Services Provider Recognized as One of the Most Innovative Companies in New England
WALTHAM, Mass., May 10, 2013 (BUSINESS WIRE) -- Affinnova, Inc., a global provider of software and services used by companies to dramatically improve their innovation and marketing success rates, today announced that it has won the New England Innovation Award, sponsored by the Small Business Association of New England (SBANE).
Acceleron’s ACE-536 Preclinical Data Presentation Selected for Best Abstract at 12th International Symposium on Myelodysplastic Syndromes
Acceleron’s ACE-536 Preclinical Data Presentation Selected for Best Abstract at 12th International Symposium on Myelodysplastic Syndromes
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
T2 Biosystems Named 2013 SBANE New England Innovation Award Winner
T2 Biosystems Named 2013 SBANE New England Innovation Award Winner
LEXINGTON, Mass.--(BUSINESS WIRE)--
BG Medicine Reports 2013 First Quarter Financial Results
BG Medicine Reports 2013 First Quarter Financial Results
Abbott and bioMérieux Obtain CE Mark and Launch Galectin-3 Tests in EU
BGM Galectin-3 Revenues Coupled With Operational Discipline Drive Improved Financial Results
BG Medicine Appoints Dr. Paul Sohmer as Chief Executive Officer
BG Medicine Appoints Dr. Paul Sohmer as Chief Executive Officer
WALTHAM, Mass., May 9, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced that it has appointed Paul Sohmer, M.D., as its President & Chief Executive Officer and a member of its Board of Directors, effective immediately. Dr.
Receptos Announces Pricing of Initial Public Offering of Common Stock
Receptos Announces Pricing of Initial Public Offering of Common Stock
SAN DIEGO, May 8, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the pricing of its initial public offering of 5,200,000 shares of its common stock at an initial public offering price of $14.00 per share. The shares of Receptos' common stock are expected to begin trading on the Nasdaq Global Market under the symbol "RCPT" on May 9, 2013.